Seth P. Lerner MD, FACSProfessor, Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine; Director, Urologic Oncology, the Multidisciplinary Bladder Cancer Program, Faculty Group Practice Medical Director for the Urology Clinic, Houston, Texas
Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic.
He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer.
Dr. Lerner is author of more than 145 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 21 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer.
He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI’s Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network.
DisclosuresDr. Lerner reports the following disclosures:
- Clinical trials
- Endo, FKD, JBL (SWOG), Genentech (SWOG), UroGen, Vaxiion, Viventia
- Consultant/Advisory Board
- FerGene, Genentech, Merck, Pfizer/EMD Serono, QED Therapeutics, UroGen, Vaxiion, Verity
- Patent – TCGA classifier
- Honoraria – UroToday
Recent Contributions to PracticeUpdate:
- Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Bladder Cancer
- Maintenance Pembrolizumab After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
- Molecular Lymph Node Staging for Bladder Cancer Patients Undergoing Radical Cystectomy
- A Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer
- Effect of Smoking and Timing of Cessation on Clinical Outcome in Non–Muscle Invasive Bladder Cancer